Gyre Therapeutics (Gyre Therapeutics) FCF Margin % : 15.25% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Gyre Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was $17.3 Mil. Gyre Therapeutics's Revenue for the six months ended in Dec. 2023 was $113.5 Mil. Therefore, Gyre Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 15.25%.

As of today, Gyre Therapeutics's current FCF Yield % is 1.29%.

The historical rank and industry rank for Gyre Therapeutics's FCF Margin % or its related term are showing as below:

GYRE' s FCF Margin % Range Over the Past 10 Years
Min: 5.55 Med: 13.73 Max: 15.25
Current: 15.25

During the past 3 years, the highest FCF Margin % of Gyre Therapeutics was 15.25%. The lowest was 5.55%. And the median was 13.73%.

GYRE's FCF Margin % is ranked better than
89.72% of 1041 companies
in the Biotechnology industry
Industry Median: -145.04 vs GYRE: 15.25

Gyre Therapeutics FCF Margin % Historical Data

The historical data trend for Gyre Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics FCF Margin % Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

13.73

5.55

15.25

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
FCF Margin %	13.73	5.55	15.25

Competitive Comparison of Gyre Therapeutics's FCF Margin %

For the Biotechnology subindustry, Gyre Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's FCF Margin % falls into.

Gyre Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Gyre Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	17.306	/	113.45
	=	15.25 %

Gyre Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	17.306	/	113.45
	=	15.25 %

Gyre Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023